BlossomHill Therapeutics, Inc.

Was BlossomHill Therapeutics, Inc. am 18. September 2026 berichtet hat

Aus dem eigenen 8-K des Unternehmens.

Telefonkonferenzen zu den Ergebnissen

Für BlossomHill Therapeutics, Inc. ist kein Transkript einer Telefonkonferenz verfügbar.

Was das Management sagte

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,”

Wörtlich aus der Veröffentlichung zitiert und nur gezeigt, wenn die Einreichung es einer namentlich genannten Person zuordnet.

Wie der Kurs reagiert hat

Veröffentlichungen kommen nach Börsenschluss oder vor Eröffnung, die Bewegung ist also die der folgenden Sitzung.

Was BlossomHill Therapeutics, Inc. macht

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR ™ inhibitor for the treatment of EGFR -mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( NCT06706076 ).

Die Selbstbeschreibung des Unternehmens, wie sie am Fuß der Veröffentlichung steht.